MRKR 10-Q: SEC filing

Marker Therapeutics

Filed with the SEC on · accession 0001104659-26-128441

MRKR filed a 10-Q (quarterly report) with the SEC on Nov 16, 2026. The quarterly report: unaudited results for the quarter plus management’s comments.

Summary of the filing

Marker Therapeutics filed its quarterly 10-Q report for the period ending September 30, 2026, disclosing routine financial results, equity activity, and grant funding details.

Key details

FilerMarker Therapeutics, Inc.
Clinical trial agreement counterpartyBaylor College of Medicine
Related party / vendorWilson Wolf Manufacturing Corporation
Related party / agreement counterpartyCellReady

✦ Ask GOAX AI about this filing — what it means for MRKR, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for MRKR?

Click here

Frequently asked questions

What did MRKR file with the SEC on Nov 16, 2026?

MRKR filed a 10-Q (SEC filing). Marker Therapeutics filed its quarterly 10-Q report for the period ending September 30, 2026, disclosing routine financial results, equity activity, and grant funding details.

How do I read a 10-Q?

The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.

Other MRKR SEC filings

Get alerts when MRKR files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days